Floatz Rating
B58/100
Confidence
Indicative
Sponsor
British Columbia Cancer Agency
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06650709CT.gov NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study | — | Not Yet Recruiting | — | — | — |
NCT04918186CT.gov Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | — | Recruiting | — | — | — |
NCT04742075CT.gov Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT05187338CT.gov Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT03983954CT.gov Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | — | Active Not Recruiting | — | — | — |
NCT03899610CT.gov A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) | — | Unknown | — | — | — |
NCT03737643CT.gov Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT03699449CT.gov An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) | — | Unknown | — | — | — |
NCT03277482CT.gov Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | — | Terminated | — | — | — |
NCT03430518CT.gov Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | — | Completed | — | — | — |
Show 12 more trialsShow fewer
NCT03267589CT.gov Trial in Patients With Relapsed Ovarian Cancer | — | Completed | — | — | — |
NCT03283943CT.gov PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | — | Unknown | — | — | — |
NCT03249142CT.gov Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer | — | Completed | — | — | — |
NCT02963831CT.gov A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | — | Completed | — | — | — |
NCT03323398CT.gov Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | — | Terminated | — | — | — |
NCT02669914CT.gov MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | — | Terminated | — | — | — |
NCT02726997CT.gov Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) | — | Active Not Recruiting | — | — | — |
NCT02725489CT.gov Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | — | Completed | — | — | — |
NCT02764333CT.gov TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | — | Completed | — | — | — |
NCT02571725CT.gov PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT02431559CT.gov Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | — | Completed | — | — | — |
NCT01975831CT.gov A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | British Columbia Cancer Agency | P3 | B · 58 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| TIL | Inge Marie Svane | P2 | BB |
| Olaparib | Shandong University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Adriamycin | Genmab | P3 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Irinotecan | ARCAGY/ GINECO GROUP | P4 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Ovarian Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-ovarian-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →